Cystic fibrosis - What are the prospects for a cure?

European Journal of Internal Medicine

Volumn 25, Issue 9, 2014, Pages 803-807

  Kumar, Shankar ^a   Tana, Anand ^a   Shankar, Anu ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Ataluren; Cystic fibrosis; Cystic fibrosis transmembrane regulator; Gene therapy; Ivacaftor; Lumacaftor

Indexed keywords

CHLORIDE CHANNEL; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR; LUMACAFTOR; VIRUS VECTOR; 1,3 BENZODIOXOLE DERIVATIVE; AMINOPHENOL DERIVATIVE; AMINOPYRIDINE DERIVATIVE; QUINOLONE DERIVATIVE;

CYSTIC FIBROSIS; DEVELOPED COUNTRY; GENE THERAPY; HUMAN; LUNG DISEASE; MORBIDITY; MORTALITY; NONVIRAL GENE DELIVERY SYSTEM; REVIEW; SURVIVAL; ADULT; CHILD; DRUG EFFECTS; GENETICS; PROCEDURES;

ADULT; AMINOPHENOLS; AMINOPYRIDINES; BENZODIOXOLES; CHILD; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENETIC THERAPY; HUMANS; QUINOLONES;

EID: 84912573715     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2014.09.018     Document Type: Review

References (39)

1. Farrell PM. The prevalence of cystic fibrosis in the European Union. Journal of cystic fibrosis: official journal of the European Cystic Fibrosis Society 2008;7(5):450-3.
2. Dodge JA, Morison S, Lewis PA, Coles EC, Geddes D, Russell G, et al. Incidence, population, and survival of cystic fibrosis in the UK, 1968-95. UK Cystic Fibrosis Survey Management Committee. Archives of disease in childhood 1997;77(6):493-6.
3. Claustres M, Guittard C, Bozon D, Chevalier F, Verlingue C, Ferec C, et al. Spectrum of CFTR mutations in cystic fibrosis and in congenital absence of the vas deferens in France. Human mutation 2000;16(2):143-56.
4. Knowles MR, Durie PR. What is cystic fibrosis? The New England journal of medicine 2002;347(6):439-42.
5. UK Cystic Fibrosis Trust Registry. Cystic Fibrosis annual data report 2012. https://wwwcysticfibrosisorguk/media/316754/Registry%20Report%20-%20Summary%202012pdf; 2013.
6. Proesmans M, Vermeulen F, De Boeck K. What's newin cystic fibrosis? From treating symptoms to correction of the basic defect. European journal of pediatrics 2008; 167(8):839-49.
7. De Boeck K, Zolin A, Cuppens H, Olesen HV, Viviani L. The relative frequency of CFTR mutation classes in European patients with cystic fibrosis. Journal of cystic fibrosis: official journal of the European Cystic Fibrosis Society 2014.
8. O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009;373(9678):1891-904.
9. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proceedings of the National Academy of Sciences of the United States of America 2009;106(44): 18825-30.
10. Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. The New England journal of medicine 2010;363(21):1991-2003.
11. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. The New England journal of medicine 2011;365(18):1663-72.
12. McKone EF, Borowitz D, Drevinek P, Griese M, Konstan M, Wainwright CE. Long-term safety and efficacy of investigational CFTR potentiator, VX-770, in subjects with CF. Pediatric pulmonology Supplement 2011;46:284.
13. Davies JC, Wainwright CE, Canny GJ, Chilvers MA, Howenstine MS, Munck A, et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American journal of respiratory and critical care medicine 2013;187(11):1219-25.
14. Flume PA, Liou TG, Borowitz DS, Li H, Yen K, Ordonez CL, et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest 2012;142(3):718-24.
15. Ren HY, Grove DE, De La Rosa O, Houck SA, Sopha P, Van Goor F, et al. VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1. Molecular biology of the cell 2013;24(19):3016-24.
16. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Stack JH, Straley KS, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proceedings of the National Academy of Sciences of the United States of America 2011;108(46):18843-8.
17. Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012;67(1):12-8.
18. Boyle MP, Bell S, Konstan M, McColley SA, Kang L, Patel N. The investigational CFTR corrector, VX-809 (lumacaftor) co-administered with the oral potentiator ivacaftor improved CFTR and lung function in F508del homozygous patients: Phase II study results. Pediatric pulmonology Supplement 2012;47(S35):315.
19. http://www.hsc.nihr.ac.uk/files/downloads/2254/2555.992c773d.Lumacaftorivacafor-Jan14.pdf.
20. http://www.clinicaltrials.gov/ct2/show/NCT01225211?term=vertex+and+cystic+fibrosis&rank=3.
21. Wilschanski M, Yahav Y, Yaacov Y, Blau H, Bentur L, Rivlin J, et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. The New England journal of medicine 2003;349(15):1433-41.
22. Sermet-Gaudelus I, Boeck KD, Casimir GJ, Vermeulen F, Leal T, Mogenet A, et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. American journal of respiratory and critical care medicine 2010;182(10):1262-72.
23. Du M, M, Liu X, Welch EM, Hirawat S, Peltz SW, Bedwell DM. PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proceedings of the National Academy of Sciences of the United States of America 2008;105(6):2064-9.
24. Kerem E, Hirawat S, Armoni S, Yaakov Y, Shoseyov D, Cohen M, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008;372(9640):719-27.
25. Wilschanski M, Miller LL, Shoseyov D, Blau H, Rivlin J, Aviram M, et al. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. The European respiratory journal 2011;38(1):59-69.
26. Konstan M, Accurso F, De Boeck K, Kerem E, Rowe S, Sermet I, et al. Targeting class 1 mutations: update on ataluren as a promising treatment for nonsense mutation in CF. Pediatric pulmonology 2012;47:108-9.
27. Diamond G, Bevins CL. beta-Defensins: endogenous antibiotics of the innate host defense response. Clinical immunology and immunopathology 1998;88(3):221-5.
28. Zabner J, Couture LA, Gregory RJ, Graham SM, Smith AE, Welsh MJ. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 1993;75(2):207-16.
29. Bellon G, Michel-Calemard L, Thouvenot D, Jagneaux V, Poitevin F, Malcus C, et al. Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a phase I clinical trial. Human gene therapy 1997;8(1):15-25.
30. Zabner J, Ramsey BW, Meeker DP, Aitken ML, Balfour RP, Gibson RL, et al. Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. The Journal of clinical investigation 1996;97(6):1504-11.
31. Griesenbach U, Alton EW. Progress in gene and cell therapy for cystic fibrosis lung disease. Current pharmaceutical design 2012;18(5):642-62.
32. Griesenbach U, Inoue M, Meng C, Farley R, Chan M, Newman NK, et al. Assessment of F/HN-pseudotyped lentivirus as a clinically relevant vector for lung gene therapy. American journal of respiratory and critical care medicine 2012;186(9):846-56.
33. Gill DR, Southern KW, Mofford KA, Seddon T, Huang L, Sorgi F, et al. A placebo-controlled study of liposome-mediated gene transfer to the nasal epitheliumof patients with cystic fibrosis. Gene therapy 1997;4(3):199-209.
34. Porteous DJ, Dorin JR, McLachlan G, Davidson-Smith H, Davidson H, Stevenson BJ, et al. Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene therapy 1997;4(3):210-8.
35. Hyde SC, Southern KW, Gileadi U, Fitzjohn EM, Mofford KA, Waddell BE, et al. Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis. Gene therapy 2000;7(13):1156-65.
36. Alton EW, Stern M, Farley R, Jaffe A, Chadwick SL, Phillips J, et al. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet 1999;353(9157):947-54.
37. Hyde SC, Pringle IA, Abdullah S, Lawton AE, Davies LA, Varathalingam A, et al. CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nature biotechnology 2008;26(5):549-51.
38. Ruiz FE, Clancy JP, Perricone MA, Bebok Z, Hong JS, Cheng SH, et al. A clinical inflammatory syndrome attributable to aerosolized lipid-DNA administration in cystic fibrosis. Human gene therapy 2001;12(7):751-61.
39. https://clinicaltrials.gov/ct2/show/NCT01621867?term=gene+therapy+and+cystic+fibro.